|Bid||5.95 x 1000|
|Ask||5.98 x 1800|
|Day's Range||5.15 - 8.99|
|52 Week Range||1.23 - 22.39|
|Beta (5Y Monthly)||1.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Dec 21, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Aug 01, 2018|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for HXLearn more
Xiaobai Maimai Inc. (NASDAQ: HX) ("Xiaobai Maimai," the "Company," or "we"), today announced the appointment of Dr. Yingxian Liu as the medical consultant to the Company. Dr. Liu will work closely with management to develop the Company's cancer therapy and radiation oncology business by the Company's wholly-owned subsidiary, We Health Limited.
Xiaobai Maimai Inc. (NASDAQ: HX) ("Xiaobai Maimai", the "Company", or "we"), a social e-commerce platform in China, today announced that it plans to enter the radiation oncology services market in the U.S.
Xiaobai Maimai Inc. (NASDAQ: HX), formerly known as Hexindai Inc. ("Xiaobai Maimai", the "Company", or "we"), a social e-commerce platform in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended March 31, 2021 with the U.S. Securities and Exchange Commission ("SEC") on July 28, 2021. The annual report on Form 20-F, which contains its audited financial statements, can be accessed on the SEC's website at http://www.sec.gov as well as via the Company's inves